Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Kobold

Showing results (21-30 of 177) with videos related to

Pageof 18
Sort By:
Trends in Cancer|May 2, 2022
Utilizing chemokines in cancer immunotherapyFlorian Märkl, Duc Huynh, Stefan Endres, et al.
Immunotherapy|November 28, 2014
Modes of action of TLR7 agonists in cancer therapySebastian Kobold, Gabriela Wiedemann, Simon Rothenfußer, et al.
Deutsche Medizinische Wochenschrift (1946)|July 14, 2018
[Immuno-Oncology: A Brief Overview]Sebastian Kobold, Angela Krackhardt, Hans Schlösser, et al.
Biomedicines|February 25, 2022
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination PartnersSophia Stock, Anna-Kristina Kluever, Stefan Endres, et al.
Frontiers in Oncology|August 10, 2018
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapySebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, et al.
Nature Reviews. Drug Discovery|June 26, 2025
Metabolites as agents and targets for cancer immunotherapyMarcel P Trefny, Guido Kroemer, Laurence Zitvogel, et al.
Current Opinion in Pharmacology|May 1, 2025
Novel approaches to CAR T cell target identification in acute myeloid leukemiaGordon Victor Hoffmann, Adrian Gottschlich, Marion Subklewe, et al.
Human Immunology|May 4, 2010
Autoantibodies against tumor-related antigens: incidence and biologic significanceSebastian Kobold, Tim Lütkens, Yanran Cao, et al.
Vaccines|November 11, 2022
Migratory Engineering of T Cells for Cancer TherapyStefanos Michaelides, Hannah Obeck, Daryna Kechur, et al.
Clinical & Developmental Immunology|January 15, 2011
Prognostic and diagnostic value of spontaneous tumor-related antibodiesSebastian Kobold, Tim Luetkens, Yanran Cao, et al.
Pageof 18

Showing results (21-30 of 177) with videos related to

Sort By:
Pageof 18
Trends in Cancer|May 2, 2022
Utilizing chemokines in cancer immunotherapyFlorian Märkl, Duc Huynh, Stefan Endres, et al.
Immunotherapy|November 28, 2014
Modes of action of TLR7 agonists in cancer therapySebastian Kobold, Gabriela Wiedemann, Simon Rothenfußer, et al.
Deutsche Medizinische Wochenschrift (1946)|July 14, 2018
[Immuno-Oncology: A Brief Overview]Sebastian Kobold, Angela Krackhardt, Hans Schlösser, et al.
Biomedicines|February 25, 2022
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination PartnersSophia Stock, Anna-Kristina Kluever, Stefan Endres, et al.
Frontiers in Oncology|August 10, 2018
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapySebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, et al.
Nature Reviews. Drug Discovery|June 26, 2025
Metabolites as agents and targets for cancer immunotherapyMarcel P Trefny, Guido Kroemer, Laurence Zitvogel, et al.
Current Opinion in Pharmacology|May 1, 2025
Novel approaches to CAR T cell target identification in acute myeloid leukemiaGordon Victor Hoffmann, Adrian Gottschlich, Marion Subklewe, et al.
Human Immunology|May 4, 2010
Autoantibodies against tumor-related antigens: incidence and biologic significanceSebastian Kobold, Tim Lütkens, Yanran Cao, et al.
Vaccines|November 11, 2022
Migratory Engineering of T Cells for Cancer TherapyStefanos Michaelides, Hannah Obeck, Daryna Kechur, et al.
Clinical & Developmental Immunology|January 15, 2011
Prognostic and diagnostic value of spontaneous tumor-related antibodiesSebastian Kobold, Tim Luetkens, Yanran Cao, et al.
Pageof 18